10 news items
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
12 Jun 24
as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
3 Jun 24
, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
BTBT
INBS
MGOL
24 May 24
earnings surprise. CEO and CFO will present at a virtual conference on May 30, offering investors access to webcast materials on the company's site
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGN
23 May 24
will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGN
20 May 24
will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's
0dpl8inmqpr ub8ldjw1cpiefjgoun
NKGN
16 May 24
, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties
910hyy uuo7attstz1lgs794sv4ufvsdiulrlde79o6mfmnceekoz3
NKGN
25 Apr 24
as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its
fpz023m8lp5tjaugu0srmyzptoqdo6nncqbowgfx6myuffxx5v5o1fk3l8
NKGN
24 Apr 24
will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development
sq5wr369vs0wg87zhmdtu6w1wrkogw398md2ok3aiv 0j4v2
NKGN
11 Apr 24
will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's
qudjiuq9zy7 kw0
NKGN
25 Mar 24
; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional
- Prev
- 1
- Next